Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc. · Webcasts, Transcripts & Audio

Track ABCL — free

Use ABCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.74 -0.17 (-1.22%) At close · Oct 2
Rebalance outlook locked
Market Cap
$3.94B
Shares
306.61M
Volume · Oct 2 3.71M Avg daily vol (3M) 6.75M

AbCellera Biologics Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for AbCellera Biologics Inc. (ABCL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼84.5% $21.54M −$29.89M '22 Q4 23-02-21 ▼96.1% $12.19M −$40.11M '23 Q1 23-05-04 ▼78.1% $10.06M −$30.53M '23 Q2 23-08-03 ▼93.5% $6.60M −$28.61M '23 Q3 23-11-02 ▼57.4% $9.18M −$47.15M '23 Q4 24-02-20 ▼18.4% $9.95M −$40.61M '24 Q1 24-05-07 ▼27.2% $7.32M −$36.93M '24 Q2 24-08-06 ▼1.4% $6.51M −$51.11M '24 Q3 24-11-04 ▼45% $5.05M −$34.21M '24 Q4 25-02-27 ▼57.5% $4.24M −$45.62M '25 Q1 25-05-08 ▲133.3% $17.08M −$34.73M '25 Q2 25-08-07 ▲37.6% $8.96M −$57.12M '25 Q3 25-11-06 ▲788.4% $44.85M −$8.95M '25 Q4 26-02-24 ▲96.3% $8.31M −$43.16M '26 Q1 26-05-11 LATEST ▼76.3% $4.05M −$55.43M '26 Q2 26-08-05
Earnings call
FY26 · Q3
2026-11-09
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
Positive tone Business development deals (Vertex, Jazz, AbbVie) T-cell engagement (TCE) platform and partnerships ABCL635 Phase 2 in VMS/menopause
Revenue
$4.05M
▼ 76.3% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
AbCellera Biologics Inc. (ABCL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-11
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
Confident tone ABCL 635 Phase II readout Dosing strategy and PK/PD Pipeline priorities and catalysts
Revenue
$8.31M
▲ 96.3% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-21
AbCellera Biologics Inc. (ABCL) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Confident tone Pipeline expansion and development candidates ABCL635 Phase II readout Liquidity and financial position
Revenue
$44.85M*
▲ 788.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
Positive tone Clinical pipeline progress Liquidity and financial position Partner-initiated programs
Revenue
$8.96M
▲ 37.6% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript
Confident tone ABCL635 vasomotor symptoms program ABCL575 atopic dermatitis program Pipeline expansion and ABCL688
Revenue
$17.08M
▲ 133.3% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript
Positive tone ABCL635 program (NK3R antibody for menopausal VMS) Clinical milestones and timing Differentiation vs. small molecule NK3R antagonists
Revenue
$4.24M
▼ 57.5% YoY
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
Positive tone Facilities and platform investments Lead programs ABCL635 and ABCL575 Reduced partnership activity
Revenue
$5.05M*
▼ 45% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript
Positive tone Liquidity and cash runway Platform and facility build-out Partnering strategy shift to co-development
Revenue
$6.51M
▼ 1.4% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
AbCellera Biologics Inc. (ABCL) Q2 2024 Earnings Call Transcript
Positive tone TCE platform programs Strategic partnerships and business development Revenue and financial trends
Revenue
$7.32M
▼ 27.2% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
Positive tone TCE platform and technology Strategic partnerships and deal-making Internal pipeline advancement
Revenue
$9.95M
▼ 18.4% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript
Confident tone Internal programs ABCL635 and ABCL575 progress Manufacturing build-out and forward integration Partnerships and royalty portfolio
Revenue
$9.18M*
▼ 57.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript
Revenue
$6.60M
▼ 93.5% YoY
Diluted EPS
$-0.10
▼ 225% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript
Revenue
$10.06M
▼ 78.1% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript
Revenue
$12.19M
▼ 96.1% YoY
Diluted EPS
$-0.14
▼ 125.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
AbCellera Biologics Inc. (ABCL) Q4 2022 Earnings Call Transcript
Revenue
$21.54M*
▼ 84.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript
Revenue
$101.38M
▲ 1740.6% YoY
Diluted EPS
$0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Call Transcript
Revenue
$45.92M
▲ 66.1% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
AbCellera Biologics Inc. (ABCL) Q1 2022 Earnings Call Transcript
Revenue
$316.58M
▲ 56.2% YoY
Diluted EPS
$0.54
▲ 45.9% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript
Revenue
$139.31M*
▼ 33% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
Revenue
$5.51M
▼ 41.2% YoY
Diluted EPS
$-0.08
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript
Revenue
$27.64M
▲ 146.2% YoY
Diluted EPS
$-0.01
▼ 133.3% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
AbCellera Biologics Inc. (ABCL) Q1 2021 Earnings Call Transcript
Revenue
$202.74M
▲ 4253.5% YoY
Diluted EPS
$0.37
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-29
AbCellera Biologics Inc. (ABCL) Q4 2020 Earnings Call Transcript
Revenue
$207.91M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 webcasts
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 1 filings 1 filers Visit website Investor relations